Publications in collaboration with researchers from Oregon Health & Science University (10)

2024

  1. Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials

    Seminars in Arthritis and Rheumatism, Vol. 65

  2. OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments

    Seminars in Arthritis and Rheumatism, Vol. 65

2023

  1. Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial

    Journal of Rheumatology, Vol. 50, Núm. 4, pp. 478-487

2021

  1. Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach

    Seminars in Arthritis and Rheumatism, Vol. 51, Núm. 3, pp. 593-600

  2. European League against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 6, pp. 775-781

2018

  1. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

    The Lancet, Vol. 391, Núm. 10136, pp. 2213-2224

2016

  1. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 4, pp. 687-695

  2. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 6, pp. 1133-1138

2013

  1. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 4, pp. 482-492

2010

  1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 6, pp. 964-975